Glucose Kabipac Fresenius Kabi

Glucose Kabipac Fresenius Kabi is a sterile solution for injection that contains glucose monohydrate as the sole active ingredient. Delivered as an intravenous solution, it serves as an energy source in parenteral nutrition and for rapid correction of hypoglycemia. The product is manufactured in the European Union and is available by prescription only for clinical use. The formulation is isotonic and compatible with common infusion sets.

Glucose Kabipac is indicated for several clinical situations where an immediate source of glucose is required.

- Treatment of acute hypoglycemia in patients unable to take oral glucose, providing rapid elevation of blood glucose levels. - Inclusion as a carbohydrate source in total parenteral nutrition (TPN) formulations to deliver calibrated caloric energy. - Use in intravenous fluid and electrolyte replacement solutions to help maintain intravascular volume and osmolar balance. - Support of patients during peri‑operative fasting, prolonged starvation, or severe catabolic states where oral intake is restricted. - Management of metabolic conditions such as insulinoma or adrenal insufficiency that require controlled glucose infusion.

Glucose Kabipac may be associated with infusion‑related reactions and metabolic changes; reported events are categorized as common or serious.

Common: - Transient rise in blood glucose levels during or shortly after the infusion. - Local irritation, erythema, or mild discomfort at the IV site. - Small electrolyte shifts, such as modest changes in serum potassium or sodium. - Headache, flushing, or a feeling of warmth during administration.

Serious: - Severe hyperglycemia that may lead to osmotic diuresis or ketoacidosis in susceptible individuals. - Immediate hypersensitivity reactions, including rash, urticaria, bronchospasm, or anaphylaxis. - Fluid overload or pulmonary edema, especially in patients with cardiac or renal impairment. - Metabolic acidosis due to rapid glucose metabolism and lactate buildup.

When using Glucose Kabipac, clinicians should observe specific precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before initiating therapy to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Monitor electrolytes, especially potassium and sodium, during prolonged or high‑dose infusions. - Use aseptic technique and inspect the solution for particulate matter or discoloration before administration. - Consider contraindications such as known hypersensitivity to glucose solutions or severe hyperglycemia. - Document total carbohydrate intake when the product is part of a total parenteral nutrition regimen.

Glucose Kabipac can interact with other intravenous agents or affect metabolic control; awareness of potential interactions helps guide safe co‑administration.

Avoid: - Co‑administration with high‑dose insulin infusions without close glucose monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hyperosmolar solutions that could increase the risk of fluid overload.

Use with caution: - Concurrent use of potassium‑containing IV fluids, as rapid glucose infusion may shift potassium intracellularly. - Administration alongside diuretics that affect fluid balance, requiring careful monitoring of volume status. - Use with catecholamine vasopressors, which can alter glucose metabolism and mask hyperglycemia. - Co‑infusion with sodium bicarbonate solutions may affect acid‑base balance and should be monitored.